- Home
- FGF vs UBX Comparison
FGF vs UBX Comparison
Compare FGF & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGF
- UBX
- Stock Information
- Founded
- FGF 2012
- UBX 2009
- Country
- FGF United States
- UBX United States
- Employees
- FGF N/A
- UBX N/A
- Industry
- FGF Property-Casualty Insurers
- UBX Biotechnology: Pharmaceutical Preparations
- Sector
- FGF Finance
- UBX Health Care
- Exchange
- FGF Nasdaq
- UBX Nasdaq
- Market Cap
- FGF 28.0M
- UBX 24.6M
- IPO Year
- FGF N/A
- UBX 2018
- Fundamental
- Price
- FGF $22.01
- UBX $1.00
- Analyst Decision
- FGF
- UBX Strong Buy
- Analyst Count
- FGF 0
- UBX 1
- Target Price
- FGF N/A
- UBX $8.00
- AVG Volume (30 Days)
- FGF 35.7K
- UBX 82.0K
- Earning Date
- FGF 11-14-2024
- UBX 11-04-2024
- Dividend Yield
- FGF N/A
- UBX N/A
- EPS Growth
- FGF N/A
- UBX N/A
- EPS
- FGF N/A
- UBX N/A
- Revenue
- FGF $22,351,000.00
- UBX N/A
- Revenue This Year
- FGF N/A
- UBX N/A
- Revenue Next Year
- FGF N/A
- UBX $33.62
- P/E Ratio
- FGF N/A
- UBX N/A
- Revenue Growth
- FGF N/A
- UBX N/A
- 52 Week Low
- FGF $14.21
- UBX $1.01
- 52 Week High
- FGF $40.75
- UBX $2.02
- Technical
- Relative Strength Index (RSI)
- FGF 38.52
- UBX 28.85
- Support Level
- FGF $23.48
- UBX $1.10
- Resistance Level
- FGF $27.00
- UBX $1.23
- Average True Range (ATR)
- FGF 3.44
- UBX 0.06
- MACD
- FGF -1.21
- UBX -0.01
- Stochastic Oscillator
- FGF 1.32
- UBX 0.00
About FGF FG Financial Group Inc. (NV)
Fundamental Global Inc through its subsidiaries operates as diversified insurance, reinsurance, and investment management holding company. The company's segment includes Insurance and Asset Management. It generates maximum revenue from the Insurance segment.
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.